Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 11-13 September 2012
CVMP opinions on veterinary medicinal products.The Committee adopted by consensuspositive opinions for extension of the existing authorisations for:
CVMP opinions on veterinary medicinal products
The Committee adopted by consensuspositive opinions for extension of the existing authorisations for:
Inflacam (meloxicam), from Chanelle Pharmaceuticals Manufacturing Limited to include 5 mg/ml solution for injection for cattle and pigs, and Rheumocam (meloxicam), from Chanelle Pharmaceuticals Manufacturing Limited to include 5 mg/ml solution for injection for cattle and pigs.
More information about the above mentioned medicines, including their full indication, can be found on the Agency’s website.
The Committee adopted by consensus positive opinions for type II variation applications for:
Prilactone regarding the addition of a new flavoured tablet formulation, in a new container type, and Oxyglobin regarding changes in the manufacturing process, the manufacturer and the control laboratory of the intermediates and active substance, addition of new suppliers of raw materials, changes in the manufacturing process and manufacturers of the active substance and finished product, addition of a new supplier of the packaging material and changes in packaging of the finished product.
Renewals of marketing authorisation
The Committee adopted by consensus a positive opinion for the renewal of the marketing authorisation for Meloxivet. The Committee, having re-assessed the benefit-risk balance of this product, concluded that the quality, safety and efficacy continues to be appropriately demonstrated and, therefore, recommended the renewal of the marketing authorisation.
Community referrals and related procedures
The Committee started a procedure for Suanovil 20 and associated names, Captalin and associated names, and generic products thereof, including pending applications (spiramycin). The matter was referred to the Committee by Germany under Article 35 of Directive 2001/82/EC, due to concerns related to efficacy, antimicrobial resistance and withdrawal periods.
The Committee started a procedure for Dexadreson 2 mg/ml and associated names, and generic products thereof, including pending applications (dexamethasone). The matter was referred to the Committee by Germany under Article 35 of Directive 2001/82/EC, due to concerns related to withdrawal periods.
Maximum Residue Limits
Further to a request to amend an entry in the list of substances considered as not falling within the scope of Regulation (EC) No 470/2009, the Committee adopted a revised list (EMA/CVMP/519714/2009-Rev.11), in order to amend the maximum dose allowed for cetearyl ethylhexanoate under the heading excipients.
The document will be available on the Agency’s website.
Scientific advice
The Committee agreed six separate scientific advice requests concerning;
Follow-up advice on the clinical development of a hormone inhibitor for cows; quality, safety and clinical development of a pharmaceutical product for a parasitic indication for bees; safety and clinical development of a cardiovascular pharmaceutical product for dogs; clinical development of a cardiovascular pharmaceutical product for dogs; clinical development of an anti-inflammatory product for horses; quality, safety and clinical development of an immunological product for sheep and goats.
Minor use minor species (MUMS) / limited markets
Following the Committee’s review of three requests for classification under the MUMS/ Limited markets policy, which concerned an immunological product for cattle, an anti-parasitic product for dogs, an anti-anemic product for cats;
The CVMP considered that the anti-parasitic product for dogs was not indicated for MUMS/Limited market and was not eligible for financial incentives; and considered that the immunological product for cattle and the anti-anemic product for cats were indicated for MUMS/Limited market and were eligible for financial incentives.
Pharmacovigilance
The Committee reviewed the PSURs for Activyl, BLUEVAC BTV8, Bovilis BTV8, BTVPUR AlSap 8, Comfortis, Emdocam, Inflacam, Meloxoral, Netvax, Nobivac Myxo-RHD, Purevax Rabies, Purevax RC, Purevax RCP FeLV, Purevax RCPCh, Purevax RCPCh FeLV, Trocoxil, Veraflox, ZOLVIX and ZULVAC 1+8 Ovis,and concluded that no further action or changes to their product literature were required.
The Committee also reviewed the PSUR for Procox and recommended amendments to the special precautions for use in animals.
The Committee also reviewed the PSUR for Suvaxyn PCV and recommended changes to the nature of adverse events already included in the current product literature.
Concept papers, guidelines and SOPs
Environmental Risk Assessment
The Committee adopted an updated Questions and Answers document on the implementation of the CVMP guideline on environmental impact assessment for veterinary medicinal products in support of the VICH Guidelines GL6 (Phase I) and GL38 (Phase II). The Questions and Answers document was revised to further clarify the 2nd question regarding Phase II concerning the Koc values to use in assessing leaching to groundwater and run off to surface water
The Questions and Answers will be published on the Agency’s website.
Incident management for medicines for veterinary use
The Committee endorsed the standard operating procedure to be followed when the incident management plan for medicines for veterinary use is triggered (SOP/V/4003). The procedure was developed to ensure effective support and coordination for management of incidents and potential crises in a harmonised and transparent manner.
The SOP will be published on the Agency’s website.
Procedural announcements
Post-authorisation measures
In the context of the exercise on the quality of opinions started in 2011 together with the European Commission, the Agency has started to review the post-authorisation measures (frequently called “follow-up measures” or “FUMs”) for centrally authorised veterinary medicinal products. In collaboration with CVMP the current follow-up measures will be reclassified either as recommendations for further development or as conditions under Annex II of the opinions of the CVMP. Marketing authorisation holders affected by these changes will be informed, together with information on any actions which need to be taken.
Update of summary of product characteristics of generics following changes to the reference product
The Committee agreed that, when the text under sections 4.4 (Special warnings), 4.5 (Special precautions for use) and 4.6 (Adverse reactions) of the summary of product characteristics is amended for a reference product, the marketing authorisation holder for the generic product will be requested to submit a variation (Type IB, C.I.2.a) to amend their product information to come into line with that of the reference product.
This is consistent with the approach taken for centrally authorised medicinal products for human use and will help to ensure equality and consistency of information between products with regard to the information made available to the practitioner and the general public in the veterinary community.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News CPHI Barcelona 2023: Loading Potential – Artificial Intelligence for Pharma Manufacturing
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News CPHI Podcast Series: Start-ups take centre stage at CPHI Barcelona
The first episode of the CPHI Podcast Series since we attended CPHI Barcelona in October covers the Start-up market at the event, with expert Matthew Wise joining Editor Lucy Chard to discuss the event.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance